Regeneron Pharmaceuticals, Inc. (REGN) News

Regeneron Pharmaceuticals delivered a highly impressive first quarter, highlighted by double-digit top- and bottom-line growth. The robust performance was anchored by the continued global dominance of DUPIXENT, rapid adoption of the high-dose EYLEA HD, and strong uptake of its oncology portfolio. Alongside a newly authorized $3 billion share repurchase program, Regeneron announced a major upcoming inflection point in its financials: the Sanofi development balance will be fully repaid in the second quarter, leading to a significant step-up in collaboration profit share beginning in Q3.

Regeneron relies on massive DUPIXENT growth to aggressively fund an unprecedented expansion of its clinical pipeline, even as its legacy ophthalmology franchise navigates intense competitive headwinds. The company is actively shifting its focus toward a heavily investment-focused 2026, signaling a willingness to compress near-term margins to secure a wave of next-generation blockbuster assets.